Dosimetry of fractionated administration of 125I-labeled antibody at experimental radioimmunotargeting

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2510-2518

  Ullén, Anders ^a   Sandström, Per ^a   Rossi Norrlund, Rauni ^a   Rathsman, Sandra ^a   Johansson, Lennart ^a   Riklund Åhlström, Katrine ^a   Hietala, Sven Ola ^a   Stigbrand, Torgny ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

125I; Dosimetry; Fractionati on; Protein dose; Radioimmunolocalization; Radioimmunotargeting; Radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY I 125;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DOSIMETRY; DRUG UPTAKE; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOSCINTIGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY;

EID: 0031456782     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2510::aid-cncr25>3.0.co;2-e     Document Type: Conference Paper

References (43)

1. Goldenberg D, Larson S, Reisfeld R, Schlom J. Targeting cancer with radiolabeled antibodies. Immunol Today 1995;16: 261-3.
2. Coons T. Monoclonal antibodies: their promise and reality. Radiol Technol 1995;67:39-69.
3. Goldenberg D. Cancer radioimmunotherapy - passing through adolescence. Tumor Targeting 1995;1:233-5.
4. Blumenthal R, Sharkey R, Goldenberg D. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 1992;84:399-407.
5. Blumenthal R, Sharkey R, Goldenberg D. Overcoming dose-limiting, radioantibody-induced myelotoxicity. In: Goldenberg D, editor. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press, 1995:295-314.
6. Blumenthal R, Sharkey R, Forman D, Wong G, Hess J, Goldenberg D. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp. Hematol 1995;23:1088-97.
7. Greiner J, Guadagni F, Goldstein D, Smalley R, Borden E, Simpson J, et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992;10:735-46.
8. Kuhn J, Beatty B, Wong J, Esteban J, Wanek P, Wall F, et al. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1995;51:2335-9.
9. Nieroda C, Milenic D, Carrasquillo J, Schlom J, Greiner J. Improved tumor radioimmunodetection using a single-chain Fv and γ-interferon: potential clinical applications for radioimmunoguided surgery and γ scanning. Cancer Res 1995;55:2858-65.
10. Zlotecki R, Boucher Y, Lee I, Baxter L, Jain R. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res 1993;53:2466-8.
11. Pedley B, Begent R, Boden J, Boxer G, Boden R, Keep P. Enhancement of radioimmunotherapy by drugs modifying tumor blood flow in a colonic xenograft model. Int J Cancer 1994;57:830-5.
12. Pedley B, Boden J, Boden R, Boxer G, Flynn A, Keep P, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996;56:3293-300.
13. DeNardo G, Maddock S, Sgouros G, Scheibe P, DeNardo S. Immunoadsorption: an enhancement strategy for radioimmunotherapy. J Nucl Med 1993;34:1020-7.
14. Norrgren K, Strand S-E, Nilsson R, Lindgren L, Sjögren H-O. A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radiommunotargeting and radioimmunotherapy. J Nucl Med 1993;34: 448-54.
15. Marshall D, Pedley B, Boden J, Boden R, Begent R. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br J Cancer 1994;69:502-7.
16. Ullén A, Sandström P, Riklund Åhlström K, Sundström B, Nilsson B, Ärlestig L, et al. Use of anticytokeratin monoclonal antiidiotypic antibodies to improve tumor/nontumor ratio at experimental radioimmunolocalisation. Cancer Res 1995;55:5868-73.
17. Begent R, Bagshawe K, Pedley B, Searle F, Ledermann J, Green A, et al. Use of second antibody in radioimmunotherapy. Monogr Natl Cancer Inst 1987;3:59-61.
18. Paganelli G, Pervez S, Siccardi A, Rowlinson G, Deleide G, Chiolerio F, et al. Intraperitoneal radiolocalisation of tumors pretargeted by biotinylated monoclonal antibodies. Int J Cancer 1990;45:1184-9.
19. Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-6.
20. Sharkey R, Boerman O, Natale A, Pawlyk D, Monestier M, Losman M, et al. Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotype antibody in tumor bearing nude mice. Int J Cancer 1992;51:266-73.
21. Morrisey P, Charrier K, Bressler L, Alpert A. The influence of IL-1 treatment on the reconstitution of the hemopoitetic and immune systems after sublethal radiation. J Immunol 1988;140:4204-10.
22. Schaafsma M, Falkenburg J, Duinkerken N, Van Damme J, Altrock B, Wiemze R, et al. Interleukin-1 synergizes with granulocyte-macrophage colony stimulating factor on granulocytic colony formation by intermediate production of granulocyte colony-stimulating factor. Blood 1989;74:2398-404.
23. Morton B, Beatty B, Mison A, Wanek P, Beatty J. Role of bone marrow transplantation in yttrium-90 antibody therapy of colon cancer xenografts in nude mice. Cancer Res 1990; 50(Suppl):1008-10.
24. Appelbaum F. The influence of total dose, dose fractionation, dose rate, and distribution of total body dose irradiation on bone marrow transplantation. Semin Oncol 1993;20:3-10.
25. Meredith R, Khazaeli M, Liu T, Plott G, Wheeler R, Russel C, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992; 33:1648-53.
26. Schlom J, Molinolo A, Simpson J, Siler K, Roselli M, Hinkle G, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990; 82:763-71.
27. Schlom J, Siler K, Milenic D, Eggensperger D, Colcher D, Miller L, et al. Monoclonal antibody-based therapy of a human tumor xenograft with a lutetium-177-labeled immunoconjugate. Cancer Res 1991;51:2889-96.
28. Buchsbaum D, Khazaeli M, Liu T, Bright S, Richardson K, Jones M, et al. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Cancer Res 1995;55(Suppl):5881-7.
29. Sundström B, Johansson B, Hietala S-O, Stigbrand T. Radio-Immunolocalization in nude mice using anticytokeratin monoclonal antibodies. Tumour Biol 1990;11:158-66.
30. Riklund Åhlström K, Ullén A, Makiya R, Sundström B, Thornell L-E, Stigbrand T. Radioimmunotherapy of HeLa cell tumors in nude mice by a combination of iodine-131-labeled monoclonal antibodies against placental alkaline phosphatase and cytokeratin. Tumor Targeting 1995;1: 239-44.
31. Sundström B, Nathrath W, Stigbrand T. Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J Histochem Cytochem 1989;12:1845-54.
32. 131I-labeled human growth hormone of high specific radioactivity. J Biochem (Tokyo) 1963;89:114-23.
33. Ellet WH, Humes RM. Absorbed fractions for small volumes containing photonemitting radioactivity. MIRD Pamphlet No 8. J Nucl Med 1971;5(Suppl):25-32.
34. Delgado C, Pedley R, Herraez A, Boden R, Boden J, Keep P, et al. Enhanced tumor specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996;73:175-82.
35. Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller L, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52:1067-72.
36. Nias A. Fractionated radiotherapy. In: Nias A, editor. An introduction to radiobiology. Chichester, UK: John Wiley and Sons, Inc., 1990:256-76.
37. Sharkey R, Blumenthal R, Hansen H, Goldenberg D. Biological considerations for radioimmunotherapy. Cancer Res 1990;50(Suppl):964-9.
38. Withers H. Biological basis of radiation therapy for cancer. Lancet 1992;339:156-9.
39. Marin L, Smith C, Langston M, Quashie D, Dillehay L. Response of glioblastoma cell lines to low dose rate irradiation. Int J Radiat Oncol Biol Phys 1991;21:397-402.
40. Sharkey R, Natale A, Goldenberg D, Mattes M. Rapid blood clearance of immunoglobulin G2a and immunoglobulm G2b in nude mice. Cancer Res 1991;15:3102-7.
41. Stigbrand T, Ullén A, Sandström P, Rathsman S, Rossi Norrlund R, Riklund Åhlström K, et al. Endogenous antitumor antibody responses in nude mice. Cancer 1997;80:2404-10.
42. Yang F, Brown R, Koral K, Clavo A, Jackson G, Wahl R. Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts. Cancer Immunol Immunother 1992;35:365-72.
43. 131I-labeled monoclonal antibodies. Anticancer Res 1990;10:379-84.